Partners
Intellectual partner
Partner in Medical Science
Official Partner of the RK-Medicine Foundation
Partner of the RK-Medicine Foundation in the Business Program
Partner of the RK-Medicine Foundation
Business Program Partner
Partner
Exhibition Partner
Technology Partner
Official Supplier
Communication partner
Volunteer program partner
Strategic multimedia partner
Media Partner
Media Partner
Magnit
Public Joint-Stock Company Magnit is the holding company of a group of companies (the Company) engaged in retail via the Magnit, DIXY, Samberi, and Azbuka Vkusa store chains. Magnit is one of the top grocery retailers in Russia and leads the market in number of stores and geographical coverage. The Company has over 33 thousand outlets in 73 Russian regions as well as the Republic of Uzbekistan. Around 19 million people visit its stores every day.
The Company operates its own logistics infrastructure, which includes 56 distribution centers, an automated inventory management system, and a fleet of over 7,800 trucks.
Magnit is a unique company in Russian retail. Besides selling goods, it produces groceries under its private labels. The Company operates 20 enterprises that cultivate vegetables and manufacture dry foods and confections.
Anna Meleshina
Managing Director of PJSC Magnit
CAREER
Anna Meleshina joined Magnit in May 2019 as the Director for Corporate Relations and Sustainable Business Development. In June 2023, she was appointed the Managing Director of PJSC Magnit.
Anna has over 20 years of experience in retail and FMCG. From 2017 to 2019, she served as Coca-Cola’s Public Affairs and Communications Director for Russia and Belarus. From 2013, she held the office of Public and Government Relations and was a member of the Management Board at Lenta. Before that, she worked for over ten years at Heineken, where she rose to the position of Corporate Relations Director for Russia and was a member of the global corporate relations leadership team.
EDUCATION
1999 — Saint Petersburg State University
2007 — MBA from Henley Business School (UK).
LOGIKA MOLOKA
“Logika moloka” is a leader in the production of fresh dairy products in Russia, as well as one of the country’s leading manufacturers of baby food and plant-based alternative beverages.
The Company’s products are manufactured at 13 facilities that meet the most advanced quality and food safety standards. 90% of the Company’s products are classified as healthy nutrition. The Company produces products under brands such as Prostokvashino, ActiBio, Actimuno, Rastishka, Tyoma, Danissimo, Bio Balance, Aktual, and others. Plant-based alternative beverages are produced under the Planto brand.
PJSC «PROMOMED»
PJSC «PROMOMED» is a leading innovative biopharmaceutical company with significant growth potential in promising segments of the pharmaceutical market. The company's structure includes its own unique world-class R&D center and a high–tech manufacturing facility - «BIOKHIMIK» plant. Thanks to this, PROMOMED implements the full-cycle production concept "from idea to molecule, from molecule to patient". The company is developing a diversified portfolio of over 360 medicines in the top 10 segments of the pharmaceutical market, including those that have no analogues in Russia. Based on its own developments, PROMOMED produces drugs for the treatment of socially significant diseases: oncological, neurological, rheumatic, infectious disease, diabetes mellitus, obesity, and others. The company is an active participant in the system ensuring national drug security and import independence.
Petr Bely
Founder and Chairman of the Board of Directors of PJSC «PROMOMED»
He has over 25 years of experience in healthcare sector. In 2005, he founded PROMOMED, which is now the leader of the Russian biopharmaceutical market with proprietary innovative products and biotechnological developments. On July 12, 2024, PROMOMED successfully conducted its Initial Public Offering (IPO).
Petr Bely regularly participates in scientific forums, conferences, and other industry events. He actively contributes to developing human resources within the Russian pharmaceutical sector. Holder of an Advanced Doctorate in Medical Sciences, author of numerous scientific publications. Holder of Pirogov’s order for merits in pharmaceutical manufacturing.
Education
Moscow State University of Medicine and Dentistry named after A. I. Evdokimov
Ozon
Ozon is an online platform uniting more than 750,000 entrepreneurs and 65 million active buyers. Users are able to choose from a wide assortment of 400 million products offered by sellers on the platform – 90% of the marketplace’s GMV is generated by sales of their products. The company provides digital, logistics, and advertising services to help entrepreneurs boost their online sales.
Ozon provides equal access to online shopping with convenient delivery for 130 million Russian residents who are covered by pick-up points within walking distance. The company manages more than 5 million square meters of logistics infrastructure across 100+ towns and cities, from Kaliningrad to Khabarovsk.
The company is also expanding into other verticals, including fintech services by Ozon Bank, rapid delivery of food and other products by Ozon Fresh, and booking services by Ozon Travel.
Igor Zimin
General Director of Ozon Holding
A Russian manager in the field of business development for IT and integration solutions, an expert in the digitalization of public administration.
Has over 20 years of business management experience as a head of enterprises in the telecommunications and financial sectors.
From 2017 to 2022 - Vice President of PJSC Rostelecom, where he ensured a sustainable business growth model in the field of digital solutions for federal and regional government bodies. Has significant practical experience in building a unified digital infrastructure for government customers in more than 70 regions of the country in the areas of "Smart City," "Safe City," "Intelligent Video Analytics," "Energy Efficiency," "Digital Social Services," and others.
Director for Interaction with Public Authorities at Internet Solutions LLC (OZON), General Director of Ozon Holding
Medtech.Moscow
Medtech.Moscow was established on the initiative of the Mayor of Moscow in February 2022 to accelerate the creation and integration of scientific developments into clinical practice.
Here, Moscow doctors, together with scientists from leading Russian research centers and start-ups, create new technologies and refine existing solutions for their accelerated implementation in the city's healthcare system. The Center supports scientific projects at all stages, including examination, patent protection, certification, obtaining registration certificates and organizing mass production.
The main areas of activity include biotechnology, genetic and cellular technologies, the development of new materials and implants, 3D bioprinting and artificial intelligence.
The Moscow Mayor's grant program, implemented by Medtech since 2022, has become one of the key tools for supporting innovative developments.
More than 1 billion rubles are allocated annually for the development, testing and implementation of advanced diagnostic, treatment and rehabilitation methods. During this time, 178 scientific studies have been supported, some of which have been applied for the first time not only in Russia, but also in the world.
All conditions have been created in the Technopark of Medtech.Moscow for the successful development of innovative medical technologies. The support programs available to residents and research teams help attract grants from federal and city development institutes, attract investments from Russian venture funds, and successfully complete the registration process for medical technologies.
Swixx Group
Swixx Group is one of the largest commercialization platforms representing the portfolio of pharmaceutical companies in those markets in which they choose not to enter or decide to exit.
Swixx Group of companies and affiliates operates across multiple countries in Central and Eastern Europe, Greece, Eurasia and several CIS countries, the Middle East and Latin America.
With more than 1,600 employees and sales which exceeded 1.1 billion Euros in 2024, the company is one of the fastest-growing independent commercialization platforms for biopharma globally.
Swixx has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and self-medication talent under one roof.
For more information about Swixx, please visit:
Alisa Dzhangiryants
Deputy General Director, Market Access and Oncology, Swixx Healthcare LLC.
Alisa has over 20 years of experience in the pharmaceutical industry.
She worked at Roche for about 10 years in Marketing Department.
In 2012, Alisa joined Bristol-Myers Squibb as Project Manager for Immunology and Oncology in Market Access Department.
In 2014, she moved to the position of Regional Market Access Managers Head.
From 2017 to 2021, she held the position of Market Access and Pricing Department Director, during which time Alisa also had experience as Commercial Director and Acting General Director.
Since December 2021, she has been transferred to the position of Oncology Department Director.
In June 2022, Alisa joined Swixx Healthcare, as a Director of Oncology and Market Access Departments. Since January 2023, she has held the position of Deputy General Director.
Alisa graduated from the 1st Moscow State Medical University I.M. Sechenov, received a PhD in Pharmaceutical Sciences.
GENERIUM
GENERIUM is a full—cycle Russian innovative research and production company, a leader in the orphan segment of the Russian pharmaceutical market. The company meets the needs of the Russian healthcare system in medicines, means of prevention and diagnosis of complex hereditary, socially significant diseases. The company's own R&D park is capable of developing medicines from the creation of a molecule to the start of industrial production in accordance with international GLP and GCP standards. The production sites are organized in strict accordance with international GMP standards.
Ryazan State Medical University named after Academician I.P. Pavlov (RyazSMU)
Ryazan State Medical University is one of the leading medical universities in Russia, where the traditions of the classical medical school are combined with modern educational technologies and scientific research. Today the University educates more than 8,000 students, including over 1,000 international students from 56 countries.
Ryazan State Medical University brings together those who choose medicine as their vocation. The University develops scientific schools, offers residency and lifelong medical education programs, and provides modern laboratories, simulation centers and clinical facilities that allow students to gain practical professional skills.
The special atmosphere of the University is shaped by mentorship, active academic and student life, as well as volunteer and social initiatives.
Ryazan State Medical University is a university of opportunities where knowledge becomes professional experience, scientific ideas grow into real projects, and the dream of becoming a doctor turns into a conscious life choice.
Roman Kalinin
Rector of Ryazan State Medical University. He is Doctor of Medical Sciences, Professor and Honored Scientist of the Russian Federation.
Professor Kalinin graduated from Ryazan State Medical University in 2000. He completed his postgraduate training at the Department of Normal and Topographic Anatomy with a course in Vascular Surgery and subsequently built his academic career at the University, serving as Assistant and later Professor at the Department of Angiology, Vascular and Operative Surgery.
He held several academic leadership positions, including Deputy Dean of the Faculty of General Medicine (2004–2007) and Dean of the Pre-University Training Faculty (2008–2011). In January 2011 he was appointed Acting Rector, and on February 7, 2012 he was officially appointed Rector of the University by the Ministry of Health and Social Development of the Russian Federation.
Professor Kalinin is a recognized researcher in vascular surgery and angiology. He is the author of more than 600 scientific publications and holds 47 patents for inventions. He serves as a member of the Council of the Association of Phlebologists of Russia, a full member of the European Society for Vascular Surgery, and a member of the Russian Union of Rectors.
For his contribution to medical science and education he has been awarded the N.A. Semashko Medal and the Honorary Badge “For Services to the Ryazan Region.”
FSBI NMRRC of the Ministry of Health of the Russian Federation
FSBI NMRRC of the Ministry of Health of the Russian Federation today is one of the largest oncological and radiological clusters in Russia, the leading institution in radiology, a reference center in the field of pathomorphological research and radiation diagnostics and therapy. Since 2020 it is also the base organization of the CIS member states in the field of oncology.
Two national registers operate on the basis of National Medical Research Center of Radiology of the Ministry of Health of Russia: Cancer - register and the National Radiation - Epidemiological Register.
The Center has a full range of modern diagnostics and complex and combined methods of treatment of cancer patients. The center has in its arsenal all types of modern beam installations, including Gamma and Cyber knives, the first Russian made proton accelerator “Prometheus”. Center implements such innovative technologies such as HIPEC and PIPAC, X-ray surgical methods of treatment, radionuclide and brachytherapy.
The Center has patented and is actively applying a method for preserving the reproductive functions of cancer patients using cryopreservation of genetic material.
A unique for Russia department of reconstructive plastic surgery of radiation injuries has been created.
The Center is one of the leaders in the field of Nuclear Medicine, development of Russian radiopharmaceuticals and their implementation in clinical practice. Nuclear medicine technologies in combined and complex treatment provide significant / additional therapeutic benefits for both oncological and non-oncological diseases.
The Pharmacy manufactures innovative radiopharmaceuticals based on 188Re, 177Lu and 225Ac radionuclides developed at the Center for the treatment of metastatic prostate cancer, primary and metastatic liver cancer, metastatic skeletal lesions and knee joint chronic synovitis.
FSBI "NMRC TPM" of the Ministry of Health of Russia
The Federal State Budgetary Institution "National Medical Research Center for Therapy and Preventive Medicine" of the Ministry of Health of the Russian Federation is a leading scientific and medical institution. The Center provides specialized, including high-technology, medical care in key profiles: therapy, cardiology, cardiovascular surgery, and neurology. Patient examination and treatment are conducted based on evidence-based medicine data and international clinical guidelines, in close collaboration with research staff. The Center's personnel (including Academicians of the Russian Academy of Sciences, Professors, and Doctors of Science) are leaders in various fields of medicine, members of international scientific societies, and participate in the development of national programs for the prevention and treatment of cardiovascular diseases and metabolic disorders.
Oxana Drapkina
Professor, doctor of medical sciences, Academician of the Russian Academy of Sciences, Chief Specialist in Therapy and General Medical Practice of the Ministry of Health of the Russian Federation, Director, National Research Center for Therapy and Preventive Medicine
In 1992, she graduated with honors from the I.M. Sechenov Moscow Medical Academy (now known as the I.M. Sechenov First Moscow State Medical University). From 1992 to 1997, she completed her clinical residency training and worked in the intensive care and resuscitation unit at the clinic of propaedeutics of internal diseases.
From 1997 to 2015, she conducted pedagogical and scientific activities at the Department of Propaedeutics of Internal Diseases at the I.M. Sechenov Moscow Medical Academy, where she successively held the positions of Assistant (1997–2008) and then Professor (2008–2015). In 1999, she defended her dissertation for the degree of Candidate of Medical Sciences (PhD equivalent), and in 2004, her doctoral dissertation.
In 2015, she joined the Federal State Budgetary Institution "National Medical Research Center for Preventive Medicine" of the Ministry of Health of Russia as the First Deputy Director for Scientific and Medical Work. In 2016, she was elected a Corresponding Member of the Russian Academy of Sciences (RAS).
In 2017, she was appointed to the position of Director of the Federal State Budgetary Institution "National Medical Research Center for Therapy and Preventive Medicine" (FSBI "NMRC TPM") of the Ministry of Health of Russia. Since 2017, she has been the Chief Therapeutist of the Ministry of Health of the Russian Federation. In 2022, she was elected a Full Member (Academician) of the Russian Academy of Sciences specializing in "therapy".
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (www.sechenov.ru) is the oldest Russian medical university with rich traditions of scientific schools, which allow an effective combination of fundamental and applied research, experimental and clinical approbation of results, their implementation in the educational process and clinical practice.
Бионова
Bionova is a brand of healthy everyday food products, founded in 2014. Today, the brand includes several product lines: sugar-free crunchy granola, chicory with extracts, sugar substitutes and sweeteners, healthy snack bars, and a range of protein products (granola, bars, porridges, soups, shakes, etc.). The brand's mission is not just to create food to satisfy hunger, but to ensure it is functional, with a clean ingredient list and the maximum amount of beneficial
Alexandra Gudimova
Founder of the Bionova brand, Marketing Director at NovaProdukt AG
Born in Moscow, she graduated from the Moscow State Academy of Choreography, received a bachelor's degree from MIRBIS, and a master's degree from HSE University. In 2014, she founded the healthy food brand Bionova as part of NovaProdukt AG LLC (a manufacturer of dietary, diabetic, and fortified food products, and a supplier of raw materials to the Russian food industry).